Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era
Pharmaceuticals · 20.05.2026 · 19 (5) · 799
DOI: 10.3390/ph19050799 ↗Kurz gefasst
Kommentar in der Zeitschrift Pharmaceuticals, online erschienen am 20.05.2026. Verfasst von Anees Bahji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
The overdose crisis in North America is increasingly driven by illicitly manufactured fentanyl and other high-potency synthetic opioids, which are associated with severe and unpredictable opioid-induced respiratory depression (OIRD). Current pharmacologic strategies to prevent fatal overdose have largely emphasized downstream rescue through opioid antagonism (e.g., naloxone), leaving limited attention to upstream pharmacologic modification of respiratory risk. In this Opinion article, we argue that buprenorphine should be reframed not only as a treatment for opioid use disorder (OUD), but also as a pharmacologic modifier of OIRD risk in fentanyl-dominant drug markets. Drawing on its partial μ opioid receptor agonism, ceiling effect on respiratory depression, and exceptionally high receptor affinity, we describe how buprenorphine can displace full agonists while limiting respiratory suppression. We further situate this pharmacology within emerging population-level observations from North American fentanyl contexts, suggesting reduced overdose mortality among individuals receiving opioid agonist therapy, particularly buprenorphine. In fentanyl-dominant drug markets, reframing buprenorphine as a modifier of respiratory risk has direct implications for clinical messaging about overdose protection, medication selection for individuals with ongoing illicit opioid use, and policy approaches aimed at reducing opioid-related mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
- Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N4Z6, Canada.
- Canadian Centre of Recovery Excellence, Edmonton, AB T6E 5A6, Canada.
- Recovery Alberta, Edmonton, AB T5J 3E4, Canada.
- Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
ORCID-Profile: Anees Bahji, Nathaniel Day
Zitieren
APA
Bahji, A., Ghauri, I., Mathew, N., Day, N., & Tanguay, R. (2026). Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era. Pharmaceuticals, 19(5), 799. https://doi.org/10.3390/ph19050799
Vancouver
Bahji A, Ghauri I, Mathew N, Day N, Tanguay R. Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era. Pharmaceuticals. 2026;19(5):799. doi:10.3390/ph19050799
BibTeX
@article{Bahji2026,
author = {Bahji, Anees and Ghauri, Imran and Mathew, Nickie and Day, Nathaniel and Tanguay, Robert},
title = {Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {799},
doi = {10.3390/ph19050799}
}
EUVIMED